JP2004518674A5 - - Google Patents

Download PDF

Info

Publication number
JP2004518674A5
JP2004518674A5 JP2002557947A JP2002557947A JP2004518674A5 JP 2004518674 A5 JP2004518674 A5 JP 2004518674A5 JP 2002557947 A JP2002557947 A JP 2002557947A JP 2002557947 A JP2002557947 A JP 2002557947A JP 2004518674 A5 JP2004518674 A5 JP 2004518674A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002557947A
Other languages
English (en)
Japanese (ja)
Other versions
JP4608183B2 (ja
JP2004518674A (ja
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed filed Critical
Priority claimed from PCT/GB2002/000184 external-priority patent/WO2002057270A1/en
Publication of JP2004518674A publication Critical patent/JP2004518674A/ja
Publication of JP2004518674A5 publication Critical patent/JP2004518674A5/ja
Application granted granted Critical
Publication of JP4608183B2 publication Critical patent/JP4608183B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002557947A 2001-01-17 2002-01-17 クルジパインおよび他のシステインプロテアーゼの阻害剤 Expired - Fee Related JP4608183B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27535901P 2001-03-13 2001-03-13
PCT/GB2002/000184 WO2002057270A1 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (3)

Publication Number Publication Date
JP2004518674A JP2004518674A (ja) 2004-06-24
JP2004518674A5 true JP2004518674A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4608183B2 JP4608183B2 (ja) 2011-01-05

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557947A Expired - Fee Related JP4608183B2 (ja) 2001-01-17 2002-01-17 クルジパインおよび他のシステインプロテアーゼの阻害剤

Country Status (20)

Country Link
US (2) US7425562B2 (cg-RX-API-DMAC7.html)
EP (1) EP1362052B1 (cg-RX-API-DMAC7.html)
JP (1) JP4608183B2 (cg-RX-API-DMAC7.html)
KR (1) KR100860067B1 (cg-RX-API-DMAC7.html)
CN (1) CN1269822C (cg-RX-API-DMAC7.html)
AT (1) ATE356130T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002219397B2 (cg-RX-API-DMAC7.html)
BR (1) BR0206501A (cg-RX-API-DMAC7.html)
CA (1) CA2436462C (cg-RX-API-DMAC7.html)
CY (1) CY1106640T1 (cg-RX-API-DMAC7.html)
DE (1) DE60218633T2 (cg-RX-API-DMAC7.html)
DK (1) DK1362052T3 (cg-RX-API-DMAC7.html)
ES (1) ES2281516T3 (cg-RX-API-DMAC7.html)
IL (2) IL156774A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006224A (cg-RX-API-DMAC7.html)
NO (1) NO328208B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ526913A (cg-RX-API-DMAC7.html)
PT (1) PT1362052E (cg-RX-API-DMAC7.html)
RU (1) RU2329266C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002057270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1446392A1 (en) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
CN100354276C (zh) * 2002-07-16 2007-12-12 阿姆拉医疗有限公司 生物活性化合物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
DE602005019971D1 (de) * 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
PL1865940T3 (pl) * 2005-03-21 2013-06-28 Virobay Inc Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JP5587790B2 (ja) * 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
CN106963760A (zh) * 2012-08-30 2017-07-21 国立大学法人东京大学 体内寄生虫防治剂在制备防治体内寄生虫的药物中的用途
CN106279188A (zh) * 2016-07-21 2017-01-04 青岛科技大学 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DE3601226A1 (de) * 1986-01-17 1987-07-23 Bayer Ag Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln
RU2137768C1 (ru) * 1993-12-15 1999-09-20 Мерк энд Ко, Инк. Ингибиторы hiv протеазы
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en) 1996-08-28 2001-01-10 Smithkline Beecham Corp CYSTEINE PROTEASE INHIBITORS
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
IL155961A0 (en) 2000-11-17 2003-12-23 Medivir Uk Ltd Cysteine protease inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors

Similar Documents

Publication Publication Date Title
RU2329266C2 (ru) Ингибиторы крузипаина и других цистеинпротеаз
CN110698408B (zh) 用于治疗沙粒病毒感染的抗病毒药物
EP3356346B1 (en) Thalidomide analogs and methods of use
EP1614676A4 (en) CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
AR025276A1 (es) El uso de un compuesto que es un derivado de 2-amino-1,3-tiazol, un compuesto que es un derivado de 2-amino-1,3-tiazol, un procedimiento para producirlo y una composicion farmaceutica que lo comprende
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2011528713A5 (cg-RX-API-DMAC7.html)
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
RU2017106172A (ru) Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
DE602005023782D1 (de) Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit
JP2017511377A5 (cg-RX-API-DMAC7.html)
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
NO934098L (no) Galaninantagonist
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
JP2004520365A5 (cg-RX-API-DMAC7.html)
JP7746165B2 (ja) Nurr1受容体調節因子
RU2006121547A (ru) Циклоалкильные производные 3-гидрокси-4-пиридинонов